Immunomedics Presents New Data on Solid Tumor Therapy Candidate

Immunomedics said Wednesday morning it presented new data for sacituzumab govitecan (IMMU-132) at its investor R&D event.

The company noted the solid tumor therapy candidate is being developed for four indications: metastatic triple-negative breast cancer, urothelial cancer, small-cell and non-small-cell lung cancer.

Immunomedics said it plans to submit a biological license application to the Food and Drug Admininstration for accelerated approval of the therapy candidate in triple-negative breast cancer patients in mid-2017.

Leave a Comment